A molecule with similar or better activity against eIF2alpha dephosphorylation and with improved formulation, pharmacokinetics, and distribution attributes could be useful for research and possibly as a therapy in ALS or other neurodegenerative conditions. Here, EIF2S1 is linked to amyotrophic lateral sclerosis.